rls-0071
PeptideexperimentalCOVID-19
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2020 (NCT04574869)
Timeline
Indications
Mechanism of action
- Complement C1sINHIBITOR
C1S inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06343792 | Phase 2 | Aug 31, 2024 | CTI Clinical Trial and Consulting Services, ReAlta Life Sciences, Inc. |
| NCT06175065 | Phase 2 | Dec 31, 2023 | ReAlta Life Sciences, Inc. |
| NCT05778188 | Phase 2 | Jul 27, 2023 | Premier Research Group, ReAlta Life Sciences, Inc. |
| NCT05351671 | Phase 1 | May 23, 2022 | FGK Clinical Research GmbH, ReAlta Life Sciences, Inc. |
| NCT05298787 | Phase 1 | Jan 13, 2021 | ReAlta Life Sciences, Inc. |
| NCT04574869 | Phase 1 | Oct 31, 2020 | ReAlta Life Sciences, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ReAlta Life Sciences, Inc. | For profit | 6 | 6 | 2 | 2020 |
| CTI Clinical Trial and Consulting Services | For profit | 1 | 0 | 1 | 2024 |
| FGK Clinical Research GmbH | For profit | 1 | 0 | 1 | 2022 |
| Premier Research Group | For profit | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1